TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05494099

Intervention type: PROCEDURE
Intervention: endoscopic maxillary mega-antrostomy
Description: a mucosal sparing technique that facilitates mucus clearance and sinus irrigation in terminally dysfunctional maxillary sinuses. EMMA involves extending the antrostomy through the posterior half of the inferior turbinate down to the floor of the nose, creating a significantly enlarged antrostomy.

Intervention type: PROCEDURE
Intervention: Endoscopic Modified Medial Maxillectomy
Description: In this approach, the maxillary sinus is operated upon, while the inferior turbinate and nasolacrimal duct are preserved.

Intervention type: PROCEDURE
Intervention: Modified endoscopic pre-lacrimal approach
Description: The approach involves making a curved mucosal incision on the lateral nasal wall just anterior to the head of the inferior turbinate. The nasal mucosa was then undermined off the lateral nasal wall. The maxillary sinus was entered with a chisel, and the medial bony wall of the maxillary sinus removed.
Study: NCT06422559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transmagnetic stimulation
Description: Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transmagnetic stimulation
Description: Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
Study: NCT05688566

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pinnacle trainer
Description: The pinnacle trainer (S776MA, SportsArt, Taiwan) was used in this study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pinnacle trainer
Description: The pinnacle trainer (S776MA, SportsArt, Taiwan) was used in this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pinnacle trainer
Description: The pinnacle trainer (S776MA, SportsArt, Taiwan) was used in this study.
Study: NCT06119893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: submucosal 8 mg (2 mL) dexamethasone application
Description: The mucoperiosteal flap was applied. After operation, submucosal dexamethasone 8 mg (2 mL) was applied to the operation area as a test group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: submucosal 2 mL 0.9% isotonic sodium chloride application
Description: The mucoperiosteal flap was applied. After operation, 2 mL 0.9% isotonic sodium chloride was applied to the operation area as a control group
Study: NCT05061693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: Oral; Tablet
Study: NCT05629026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-biopsies
Description: Two micro-biopsies of limb tissue will be carried out, one on the lymphedema and one in the upper limb not affected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-biopsies
Description: Two micro-biopsies of limb tissue will be carried out, one on the lymphedema and one in the upper limb not affected.
Study: NCT05119959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECD intervention for CHEUs
Description: The bi-weekly community health worker-delivered ECD 1 hour intervention using the modules from the SUPERCDZ curriculum which is a Zambian adaptation of UNICEF's Nurturing Care Framework

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for CHEUs
Description: No ECD interventions will be provided by community health workers. Children will be followed at clinics for growth and monitoring, vaccinations on a MoH approved schedule.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for CHEUs
Description: No ECD interventions will be provided by community health workers. Children will be followed at clinics for growth and monitoring, vaccinations on a MoH approved schedule.
Study: NCT06356610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Use of Test Product A in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Use of Test Product A in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Use of Test Product A in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Use of Test Product A in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Use of Test Product A in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Use of Test Product A in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product B
Description: Use of Test Product B in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product B
Description: Use of Test Product B in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product B
Description: Use of Test Product B in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product B
Description: Use of Test Product B in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product B
Description: Use of Test Product B in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product B
Description: Use of Test Product B in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product C
Description: Use of Test Product C in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product C
Description: Use of Test Product C in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product C
Description: Use of Test Product C in controlled use and ad libitum use sessions
Study: NCT05061693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: Oral; Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral; Tablet
Study: NCT06356610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product C
Description: Use of Test Product C in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product C
Description: Use of Test Product C in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product C
Description: Use of Test Product C in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product D
Description: Use of Test Product D in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product D
Description: Use of Test Product D in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product D
Description: Use of Test Product D in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product D
Description: Use of Test Product D in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product D
Description: Use of Test Product D in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product D
Description: Use of Test Product D in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Product E
Description: Use of Reference Product E in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Product E
Description: Use of Reference Product E in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Product E
Description: Use of Reference Product E in controlled use and ad libitum use sessions
Study: NCT06422559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
Study: NCT05185687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First Come, First Served
Description: Respondents will view the following description of the plan: Tests will be sent out in the order they are requested. People who request tests the quickest will get them first, no matter where they live. People who request tests later may not get any. This strategy is also known as 'First Come, First Served.'

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Random
Description: Respondents will view the following description of the plan: People who request tests will be entered into a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live, but some people may not get any tests.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disadvantaged Priority & Random
Description: Respondents will view the following description of the plan: Because COVID-19 has hit people living in disadvantaged areas of the country harder, a proportion of tests will be sent exclusively to people in these zip codes. Planners will allocate 80% of the tests using a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live. The remaining 20% are set aside exclusively for the most disadvantaged areas, again allocated with a random drawing. Some people may not get any tests. But people living in disadvantaged areas are more likely to get them.
Study: NCT05149287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: single intravenous dose of 1 g of ceftriaxone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1% lidocaine and saline
Study: NCT06356610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Product E
Description: Use of Reference Product E in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Product E
Description: Use of Reference Product E in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Product E
Description: Use of Reference Product E in controlled use and ad libitum use sessions
Study: NCT05140018

Intervention type: PROCEDURE
Intervention: Kidney Transplantation
Description: All participants will receive a kidney transplantation from a living donor or deceased donor

Intervention type: COMBINATION_PRODUCT
Intervention: Immunosuppression
Description: All participants will receive immunosuppresive drugs to prevent rejection of de kidney transplant graft.

Intervention type: PROCEDURE
Intervention: Nephrectomy (kidney donation)
Description: All kidney donors will receive a nephrectomy for kidney donation
Study: NCT05578222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200mg i.v. gtt,D1,Q3W,
Study: NCT05970809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAGA-001 (A)
Description: Use of a novel microneedle and laser device as a treatment for male patten hair loss with additional microwounding.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAGA-001 (B)
Description: Use of a novel microneedle and laser device as a treatment for male patten hair loss without additional microwounding.
Study: NCT06150131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic and strength exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Aerobic and strength exercise.
Study: NCT04822961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Senaparib-matched placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Senaparib
Description: 20 mg capsules
Study: NCT05980988

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The experimental phase of this study had last 84 days, and each patient will make 4 visits (d1, d28, d56, d84).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05766215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Education
Description: It consists of four structured phases: 1. Welcome nurse visit, 2. Diabetologic education course adapted to the detected needs, 3. Individualized follow-up through alternating quarterly appointments between nurses and endocrine physician, 4. Evaluation and discharge of the program
Study: NCT05571657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder/Recall Sent Via Preferred Method of Communication
Description: Parents of 12-17 year-old patients due for COVID-19 booster dose will receive a one-time vaccine reminder/recall via the parent's preferred method of communication (mailed letter, text message, email)
Study: NCT06389474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INM004
Description: Two doses of Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab´)2 fragments at a dosage of 4 mg/kg of body weight, 24 hours apart. Each vial contains 25 mg of protein/ml. Therefore, each subject must receive 0.16 ml/kg per dose. The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag. It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes. In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of placebo, 24 hours apart. The placebo solution has the same composition of excipients as INM004 without the active pharmaceutical ingredient, and its appearance is identical. Each subject must receive 0.16 ml/kg of placebo solution per dose. The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag. It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes. In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes
Study: NCT05564702

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional drug treatment
Description: The patients in this arm will be given doctor specified dosage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opt-IVF predicted dosage
Description: The patients in this arm will be given dosage predicted by Opt-IVF.
Study: NCT06356610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Product F
Description: Use of Reference Product F in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Product F
Description: Use of Reference Product F in controlled use and ad libitum use sessions
Study: NCT05674071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Articulation/HVT
Description: Osteopathy 1

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soft-tissue massage
Description: Osteopathy 2

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Craniosacral techniques
Description: Osteopathy 3

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination of the three interventions: HVT, soft-tissue and craniosacral techniques
Description: This intervention will use a combination of the three interventions: HVT, soft-tissue and craniosacral techniques
Study: NCT05699577

Intervention type: DIAGNOSTIC_TEST
Intervention: serum sample for ELIZA
Description: ELIZA for Ca15-3 and interferon gamma

Intervention type: DIAGNOSTIC_TEST
Intervention: serum sample for ELIZA
Description: ELIZA for Ca15-3 and interferon gamma
Study: NCT05640882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VRET
Description: 10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VRET OLFACTION
Description: 10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure with the addition of olfaction
Study: NCT05161663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-driven intervention
Description: This peer-driven intervention (PDI), modified based on respondent-driven sampling (RDS) or snowball sampling, is a chain referral approach. Index peers will be purposefully selected to reflect the diversity of African American (AA) and Hispanic/Latino (H/L) men who have sex with men (MSM) and are required to take a formal training about pre-exposure prophylaxis (PrEP) and HIV. These index peers will educate members of their social networks and encourage them to initiate PrEP. Those referred peers will schedule an appointment to complete a short survey and will be referred to our PrEP clinic if they are interested in PrEP uptake. The referred peers will serve as index peers for the following wave of recruitment. It is expected to achieve a robust sample of AA and H/L within six waves of recruitment. This PDI approach is potential to engage AA and H/L who are most at risk of HIV acquisition in PrEP uptake and could contribute to reducing the concentrated HIV epidemic.
Study: NCT02873468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florence 30 μg/mL
Description: 10 mL, oral, twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florence 60 μg/mL
Description: 10 mL, oral, twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florence 90 μg/mL
Description: 10 mL, oral, twice a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mL, oral, twice a day.
Study: NCT06542549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: The study treatment was followed by a 3-week treatment cycle. The dosing time window is ±3 days. Within 72 hours before each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, and physical status score, to evaluate the safety and tolerability of continued treatment.
Study: NCT04809038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Patient will be placed in a comfortable prone position and encouraged to maintain complete relaxation. The selected active MTrPs was prepared by wiping the area with alcohol pad, and a gauge needle with its plastic guide tube in place will be palced over the active MTrPs .a tapping motion will be used to advance the needle to a depth of 5 to 10 mm for 30 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: magnesium sulphate iontophoresis
Description: The subjects in the iontophoresis group received MgSO4 iontophoresis using an iontophoretic drug delivery system (Phoresor_IIAuto,ModelPM850,IOMED. MTrPs were examined using pincer palpation and marked by pin. MgSO4 was applied to the active positive electrode using a syringe with a concentration of 100 mg/cm2. The active electrode was placed directly over the marked area where the sensitive MTrPs were located. The dispersive electrode was applied to the skin 6 inches distal from the active electrode.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercise
Description: The patient will be placed in a comfortable and relaxed sitting position with his back supported ; one hand was placed on the side of the head applying the stretching force, while the other hand was placed on the patients shoulder applying shoulder stablization . The direction of stretched force was in flexion , side bending to the opposite side and rotation to the same side . The stretched position will be sustained for 30 seconds , then a relaxation period of 30 seconds . This procedure was repeated 3 times .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercise
Description: The patient will be placed in a comfortable and relaxed sitting position with his back supported ; one hand was placed on the side of the head applying the stretching force, while the other hand was placed on the patients shoulder applying shoulder stablization . The direction of stretched force was in flexion , side bending to the opposite side and rotation to the same side . The stretched position will be sustained for 30 seconds , then a relaxation period of 30 seconds . This procedure was repeated 3 times .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching exercise
Description: The patient will be placed in a comfortable and relaxed sitting position with his back supported ; one hand was placed on the side of the head applying the stretching force, while the other hand was placed on the patients shoulder applying shoulder stablization . The direction of stretched force was in flexion , side bending to the opposite side and rotation to the same side . The stretched position will be sustained for 30 seconds , then a relaxation period of 30 seconds . This procedure was repeated 3 times .
Study: NCT06160479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Description: Different amount of calcium supplement in pregnancy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Description: Different amount of calcium supplement in pregnancy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Description: Different amount of calcium supplement in pregnancy
Study: NCT05229315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: PD-1 Immune Checkpoint Inhibitor Combined With IMRT,used at 2 weeks before radiotherapy, once every 2 weeks, 10 cycles in total
Study: NCT06356610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Product F
Description: Use of Reference Product F in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Product F
Description: Use of Reference Product F in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Product F
Description: Use of Reference Product F in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Product F
Description: Use of Reference Product F in controlled use and ad libitum use sessions